UK Confirms Indefinite Recognition of CE-Marked Devices (October 2026): MDD Transition Extended to Align with the EU's 31 December 2028

On 21 October 2026, the UK Government and the Medicines and Healthcare products Regulatory Agency (MHRA) published their formal response to the targeted consultation on the indefinite recognition of CE-marked medical devices. The conclusion is clear: Great Britain (England, Wales and Scotland) will continue to accept CE-marked medical devices and in vitro diagnostic devices on a long-term basis, and these products will not be required to go through a separate UK approval route. The response also confirms that the existing transition arrangement for MDD devices will be aligned with the EU timetable.

One Answer, One Change: The Expiry Date

The regime itself has not been rebuilt. Only one element changes: a time-limited recognition becomes one without an end date. The response additionally confirms that the current MDD device transition will be brought into line with the EU schedule.

What Was Wrong with the Current Timetable

Under Regulation 19B of the UK Medical Devices Regulations 2002, general medical devices approved under the EU Medical Devices Directive (93/42/EEC, MDD) may currently be placed on the Great Britain market until 30 June 2028. After that date, under Regulation 19C, such products must either comply with the EU Medical Device Regulation (EU 2017/745, MDR) or undergo UKCA conformity assessment in order to continue entering the Great Britain market.

The EU has extended the deadline for transitioning certain devices to the MDR to 31 December 2028. Compared side by side, a six-month misalignment appears between 30 June 2028 and 31 December 2028: some devices that remain lawful in the EU could no longer be placed on the GB market under the original UK rules. The Government concluded that this creates a risk of supply disruption and decided to extend the UK transition period so that it matches the EU.

Under Regulations 19C and 44ZB, devices certified under the EU MDR or the EU IVDR may currently be placed on the GB market until 30 June 2030 at the latest; after that, the UKCA route applies. The question this response addresses is precisely what happens after that expiry.

The Consultation: Three Proposals, Two Adopted

The consultation ran from 16 February 2026 to 10 April 2026 and received 1,056 responses, covering device and IVD manufacturers, UK Responsible Persons (UKRPs), notified bodies, healthcare professionals, patient organisations and individuals.

• Proposal 1 — extend the MDD device transition arrangement and align it with the EU: 628 agreed (60%), 374 opposed (35%), 54 had no view.
• Proposal 2 — presented in two forms. The broad option would recognise all EU MDR and EU IVDR certified devices indefinitely; the narrow option would recognise only devices of the same or a lower UK risk classification. The broad option received 608 expressions of support (57%) and 335 objections (32%), while a further 102 respondents (10%) supported only the narrower “same or lower class” scope.
• Proposal 3 — create a separate international reliance pathway for devices classified higher in the UK than in the EU; the majority of responses did not support it.

The Government's decision was to adopt Proposal 1 and the broad option of Proposal 2, and to drop Proposal 3. The reason given for dropping it is stated plainly: the regulatory complexity created by a standalone reliance pathway is disproportionate to its likely safety benefit.

CE Recognition Does Not Remove UK Local Obligations

The response devotes a specific section to drawing the boundary: manufacturers placing CE-marked devices on the Great Britain market must still appoint a UK Responsible Person (UKRP), must still register devices with the MHRA, must still meet post-market surveillance (PMS) obligations, must still prepare technical documentation and conformity certificates in English and make them available, and must still comply with compliance, suspension, safety and information notices issued under the Medicines and Medical Devices Act 2021.

The oversight side has not been withdrawn either. The MHRA remains responsible for all devices entering the UK market, collecting reports through the Yellow Card scheme, investigating adverse incidents and allegations of non-compliance, exchanging safety signals with overseas regulators, and implementing the recommendations of the Independent Medicines and Medical Devices Safety Review (IMMDS).

On pelvic mesh victims, the response contains a dedicated paragraph: the Government acknowledges the strong opposition received, acknowledges that these experiences have damaged public trust in some devices, and lists as its response measures strengthened post-market surveillance, the introduction of unique device identification (UDI) and implant cards for UKCA devices, and raising the classification of implantable devices.

Legislative Timing and Where UKCA Stands

The response states that the MHRA will bring forward legislative changes giving effect to the first proposal and the broad option of the second proposal from the consultation. The amendments are intended to be completed before the earliest relevant transition period ends, that is, before 30 June 2028, subject to parliamentary approval. In other words, the direction is settled but the statutory text is not yet in place.

The UKCA mark continues to exist as the UK's domestic market access route, running in parallel. The Government is developing a UKCA pre-market statutory instrument to update the requirements that UKCA-marked devices must meet, and is seeking powers through primary legislation to prepare the ground for a future device licensing regime, aimed at a framework better suited to software and algorithm-driven devices, including machine-learning-based devices.

Territorial Scope: Great Britain, Not the Whole UK

One exception must be stated explicitly: this arrangement covers Great Britain. Northern Ireland continues to apply EU medical device law, with separate official guidance. The response notes that indefinite CE recognition in Great Britain also helps a single product cover supply across the whole UK market.

Sources

• GOV.UK / MHRA — Government confirms indefinite recognition of CE marked medical devices: https://www.gov.uk/government/news/government-confirms-indefinite-recognition-of-ce-marked-medical-devices (21 October 2026)
• GOV.UK — Government response to the targeted consultation on indefinite recognition of CE marked medical devices (PDF): https://assets.publishing.service.gov.uk/media/6ad76f8be9713babfbe3f755/Government_response_to_the_targeted_consultation_on_indefinite_recognition_of_CE_marked_medical_devices.pdf (21 October 2026)
• GOV.UK — Medical devices regulations: targeted consultation on the indefinite recognition of CE marked medical devices: https://www.gov.uk/government/consultations/medical-devices-regulations-targeted-consultation-on-the-indefinite-recognition-of-ce-marked-medical-devices (opened 16 February 2026, closed 10 April 2026, updated 21 October 2026)

Verification scope and access date: the full text of the above news release, the body of the consultation page and the full government response PDF (21 pages, including the executive summary, response statistics for the three proposals, the government response and next steps) were reviewed on 26 October 2026. Dates, regulation numbers (Regulations 19B, 19C and 44ZB of the Medical Devices Regulations 2002), response counts and percentages are taken from the original text of the official pages listed above.

AIMEILI Regulatory Interpretation

This is a high-impact policy decision, but its legal status must be read precisely. The UK Government has committed to indefinite recognition of CE-marked devices certified under the EU MDR and EU IVDR, and to aligning the MDD transition with the EU's 31 December 2028 endpoint, closing the six-month gap that would otherwise have opened between 30 June 2028 and 31 December 2028. However, the implementing legislative amendments are still to be laid and require parliamentary approval. Until that happens, the current rules — including the 30 June 2028 MDD cut-off and the 30 June 2030 outer limit under Regulations 19C and 44ZB — remain the operative legal baseline, and transition planning should not assume the new provisions are already in force.

The second point is that recognition of CE marking is a market access simplification, not a deregulatory measure. The UK Responsible Person requirement, MHRA device registration, post-market surveillance, English-language technical documentation and certificates, and the enforcement powers under the Medicines and Medical Devices Act 2021 all remain fully applicable. Any assumption that indefinite CE recognition removes the need for a UKRP or MHRA registration would be incorrect, and the consultation response states this boundary explicitly.

The third point concerns risk classification divergence. The Government rejected the proposal to create a separate international reliance pathway for devices classified higher in the UK than in the EU, and it adopted the broad scope of recognition rather than a class-limited version. For products whose UK classification would differ from their EU classification, the practical consequence is that CE recognition will apply, but classification, conformity assessment route and any UK-specific conditions will still need to be assessed case by case against the applicable GB rules.

Finally, the UKCA route remains in place and is being actively developed, with a pre-market statutory instrument in preparation and primary legislation being sought for a future licensing framework. Manufacturers should therefore treat UKCA not as a route being retired but as a parallel, evolving pathway whose requirements may change.

Business Impact for Manufacturers, Distributors, CROs and Regulatory Affairs Teams

• Portfolio and labelling decisions: devices holding valid EU MDR or EU IVDR certificates gain durable certainty for Great Britain; decisions to add UKCA marking can be driven by commercial and tender requirements rather than by an imminent CE cut-off.
• MDD certificate holders: the six-month gap between 30 June 2028 and 31 December 2028 is intended to be closed, but continuity depends on the enabling legislation being in place before 30 June 2028. Maintain a dual-track plan that keeps MDR transition and UKCA readiness active.
• UK Responsible Person and registration: UKRP appointments, MHRA registrations and PMS systems must remain funded and resourced for the full product lifecycle in Great Britain; these are not transition-period costs.
• Documentation: English-language technical documentation and conformity certificates must remain available on request, and post-market surveillance reporting must continue to feed MHRA notifications and information requests.
• Northern Ireland: products placed on the Northern Ireland market continue to follow EU device law; any single-SKU strategy covering the whole UK must accommodate two regulatory baselines.
• Software and algorithm-driven devices: the planned future licensing framework is intended to be more adaptable to these technologies, so regulatory affairs teams should anticipate new pre-market requirements rather than assume the current position is permanent.

Disclaimer

This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. “Indefinite recognition” describes the policy direction announced by the UK Government and the proposed legislative content; the legislative amendments remain subject to parliamentary approval, and the statutory text and effective details are subject to subsequent official publication. Different rules apply in Northern Ireland. Information may change with further official updates; for specific matters, the official original texts and the latest guidance should be relied upon.